Latest Breaking News On - Julia hofmann - Page 8 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s . AFFiRiS AGApril 27, 2021 GMT Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance Results set the ground for AFFiRiS’ potential first-in-class antibody-based systemic therapeutic modalities targeting mtHTT directly VIENNA, Austria, April 27, 2021 (GLOBE NEWSWIRE) AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific immunotherapies, announces today the presentation of

United statesJulia hofmannErica fioriniCornelia kutzerAmber southwellMc servicesDivision of neuroscienceBurnett school of biomedical sciencesAnnual huntingtonDisease therapeuticsChief technology officerAssistant professorBurnett schoolBiomedical sciencesஒன்றுபட்டது மாநிலங்களில்ஜூலியா ஹாஃப்மேன்